title: Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies.
abstract: Osteosarcoma (OSA) is the most common bone tumor affecting the dog. The veterinary options for therapeutic management of OSA are limited and prognosis for such patients is poor. Oncolytic adenoviruses are attractive tools for experimental therapeutics as they can replicate and spread within tumors to directly induce tumor destruction. However, a major impediment to systemic oncolytic adenoviruses injection is the presence of pre-existing neutralizing antibodies (Nabs). In this study, we investigated the effect of a replication-selective canine adenovirus (OCCAV) to treat OSA in the presence of Nabs and the use of canine OSA cells as carrier vehicles for evading Nabs. Our systemic biodistribution data indicated that canine tumor cells could successfully reach the tumor site and deliver OCCAV to tumor cells in an immunized mice model. Furthermore, the use of carrier cells also reduced adenovirus uptake by the liver. Importantly, OCCAV alone was not effective to control tumor growth in a pre-immunized xenograft mouse model. On the contrary, systemic antitumoral activity of carrier-cell OCCAV was evident even in the presence of circulating antibodies, which is a relevant result from a clinical point of view. These findings are of direct translational relevance for the future design of canine clinical trials.
authors.affiliation: Translational Research Laboratory, IDIBELL-Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Alcayaga-Miranda
authors.forename: M
authors.initials: M
authors.lastname: Cascallo
authors.forename: J J
authors.initials: JJ
authors.lastname: Rojas
authors.forename: J
authors.initials: J
authors.lastname: Pastor
authors.forename: R
authors.initials: R
authors.lastname: Alemany
mesh_terms: D006516:Adenoviruses, Canine / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D000818:Animals; D057134:Antibodies, Neutralizing / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000378:metabolism; D001859:Bone Neoplasms / Q000378:metabolism*; D045744:Cell Line, Tumor; D004285:Dogs; D005822:Genetic Vectors / Q000378:metabolism; D006801:Humans; D007114:Immunization; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D050504:Oncolytic Viruses / Q000235:genetics* / Q000378:metabolism; D012516:Osteosarcoma / Q000235:genetics*; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays
chemical_list: D057134:Antibodies, Neutralizing; D000970:Antineoplastic Agents